ArcherDX Personalized Cancer Monitoring (PCM) tech designated by FDA as Breakthrough Device

ArcherDX Personalized Cancer Monitoring (PCM) tech designated by FDA as Breakthrough Device

BOULDER -- ArcherDX, Inc. announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Personalized Cancer Monitoring (PCM) technology, a... Read More

Wednesday January 15, 2020 0 comments Tags: Boulder, ArcherDx, Jason Myers, FDA

ArcherDX and Illumina partner to broaden access for oncology testing

ArcherDX and Illumina partner to broaden access for oncology testing

BOULDER -- ArcherDX, Inc . announced a non-exclusive, multi-year partnership with San Diego-based Illumina, Inc. (NASDAQ: ILMN) that aims to broaden access of next generation sequencing (NGS)-based... Read More

Monday January 13, 2020 0 comments Tags: Boulder, ArcherDx, Jason Myers, Illumina, Phil Febbo

ArcherDX appoints Mark Massaro company CFO

ArcherDX appoints Mark Massaro company CFO

BOULDER -- ArcherDX, Inc. , a molecular diagnostics company developing breakthrough solutions to advance and enable the practice of personalized genomic medicine, today announced Mark Massaro has... Read More

Tuesday January 7, 2020 0 comments Tags: Boulder, ArcherDx, Mark Massaro, Jason Myers

ArcherDX closes $55M Series C financing round

ArcherDX closes $55M Series C financing round

BOULDER -- ArcherDX, Inc. , a molecular diagnostics company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, announced the close of a$55... Read More

Tuesday December 17, 2019 0 comments Tags: Boulder, ArcherDx, Jason Myers, STRATAFIDE

ArcherDX partners with Illumina to develop in-vitro diagnostic tests

ArcherDX partners with Illumina to develop in-vitro diagnostic tests

BOULDER -- ArcherDX, Inc. , a growth-stage molecular diagnostics company dedicated to developing breakthrough solutions that advance personalized genomic medicine, today announced a non-exclusive... Read More

Tuesday December 3, 2019 0 comments Tags: Boulder, ArcherDx, Illumina, Jason Myers, Phil Febbo

ArcherDX launches B Cell Receptor sequencing assays for immune repertoire characterization

ArcherDX launches B Cell Receptor sequencing assays for immune repertoire characterization

BOULDER -- ArcherDX , a leader in NGS-based fusion assays, today announced the release of Archer Immunoverse B Cell Receptor (BCR) assays to characterize the human B cell repertoire. The... Read More

Wednesday May 17, 2017 0 comments Tags: Boulder, ArcherDx, Jason Myers, Brian Kudlow